-
Pro-inflammatory lipids precede Type 1 diabetes onset in mouse model and children
Type 1 diabetes, or T1D, is an autoimmune disease in which the body’s immune cells — led by inflammatory macrophages — attack and destroy the beta cells of the pancreas that produce insulin. Researchers have long tried to unravel the signaling that provokes this attack. One of the less-studied forms…
-
COVID-19 linked to type 1 diabetes and diabetic ketoacidosis in children
The coronavirus disease (COVID-19) may cause severe disease in high-risk people, including the elderly, people with underlying health conditions such as heart disease and diabetes, and those with weakened immune systems. Though most children and adolescents seem to be spared by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the…
-
STUDY: Antibiotics in First Year of Life May Up Risk for T1DM by Age 10
Posted by Physicians Weekly | Mar 19, 2020 THURSDAY, March 19, 2020 (HealthDay News) — Antibiotic prescriptions in the first year of life are associated with an increased risk for type 1 diabetes in childhood, according to a study published online March 4 in Diabetes Care. Mona-Lisa Wernroth, from Uppsala…
-
Full interview: Genprex’s newly licensed type 1 diabetes gene therapy’s potential explained by scientist
Dr George Gittes, Professor of Surgery at the Children’s Hospital of Pittsburgh explains how and why he began working on the gene therapy licensed by Genprex (NASDAQ:GNPX). Dr Gittes says the therapy, currently undergoing pre-clinical studies, has shown data where it caused pancreatic cells to turn into insulin-producing cells. Watch…
-
Bone turnover markers decreased in children with type 1 diabetes
A cohort of children and adolescents with type 1 diabetes had markers of bone formation and bone resorption that were significantly decreased compared with children without diabetes, independent of diabetes duration and Tanner stages, according to findings published in Pediatric Diabetes. “The take-home message from the study is that bone…
-
FDA Approves Fiasp for Children With Diabetes
The FDA has approved insulin aspart injection (Fiasp, Novo Nordisk), 100 U/mL, as a new mealtime option for children with diabetes—the first fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Diabetes is one of the most common chronic conditions of childhood, with nearly 18,000 new cases…
-
Genetic differences help distinguish type 1 diabetes in children from ‘type 1.5’ in adults
Philadelphia, January, 2020–A multi-center team of researchers led by Children’s Hospital of Philadelphia (CHOP) has discovered a genetic signature that could help distinguish an adult-onset form of diabetes sharing many type 1 diabetes (T1D) characteristics from pediatric-onset T1D, opening the door to potentially more straightforward diagnostic tests for the adult…
-
Simple genetic test for type 1 diabetes being developed
For many children with type 1 diabetes, a diagnosis only comes after they find themselves hospitalized in life-threatening diabetic ketoacidosis. Researchers in Virginia hope to change that. Scientists at the Center for Public Health Genomics at the University of Virginia in Charlottesville have developed a test that they think may…
-
Unexpected viral behavior linked to type 1 diabetes in high-risk children
Viruses have long been suspected to be involved in the development of type 1 diabetes, an autoimmune disease, but consistent evidence connecting viruses to the condition has been hard to come by. Investigators at the Baylor College of Medicine, the University of South Florida, and other institutions studied samples available…
-
FDA Approves Insulin Glargine Injection for Pediatric Patients with Diabetes
2019-11-26 11:43:00 Jennifer Nessel, Assistant Editor Officials with the FDA have approved an expanded indication for insulin glargine injection (Toujeo, Sanofi) 300 Units/ml as a long-acting insulin to improve blood sugar control in adult and pediatric patients, age 6 years and older, with diabetes.1 The drug was previously approved by…
